Direct investment Tozaro raises £6.0million
Summary by AI BETAClose X
RNS 16 February 2026
Mercia Asset Management PLC
("Mercia" or the "Company" or the "Group")
Mercia direct investment Tozaro raises £6.0million
Mercia Asset Management PLC (AIM: MERC), the regionally focused, private capital asset manager with c.£2.0billion of assets under management, is pleased to announce that Tozaro Limited ("Tozaro"), a UK-based biotech company and one of the Group's direct investments, has completed a £6.0million funding round to support the commercialisation of its Smart Polymer™ technology.
The funding round was led by Mercia through a combination of direct investment (£1.3million) and investment by its third-party managed funds, alongside participation from existing third-party co-investors. Following this funding round, Mercia holds a fully diluted 11.9% direct investment in Tozaro.
The new funding will initially enable focus on improving the production of viral vectors used in advanced cell and gene therapies ("CGT"). These vectors are critical components in manufacturing life-saving treatments, where current production methods face significant challenges around efficiency, scale and cost.
Mark Payton, Chief Executive Officer of Mercia Asset Management, commented:
"There are over 70 CGT products currently on the market with over 3,400 more in development* within a segment growing rapidly, valued at over $10bn today and forecast to grow to over $100bn by 2034**. Growth, however, in this exciting new generation of biological therapeutics is being held back by the high cost of their production. Tozaro is developing an approach that will significantly reduce this cost without shouldering the risk of clinical development of the therapeutic itself. Tozaro has made significant commercial progress during the past year, moving from platform development into meaningful engagement with downstream processing partners and potential customers."
*https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies
**https://www.fortunebusinessinsights.com/cell-and-gene-therapy-market-114130#:~:text=The%20global%20cell%20and%20gene,share%20of%2040.10%25%20in%202025.
-Ends-
For further information, please contact:
|
Mercia Asset Management PLC Mark Payton, Chief Executive Officer Martin Glanfield, Chief Financial Officer
|
+44 (0)330 223 1430
|
|
Canaccord Genuity Limited (NOMAD and Joint Broker) |
+44 (0)20 7523 8000 |
|
Simon Bridges, Andrew Potts, Harry Rees |
|
|
|
|
|
Singer Capital Markets (Joint Broker) |
+44 (0)20 7496 3000 |
|
Charles Leigh-Pemberton
|
|
|
|
|
|
FTI Consulting |
+44 (0)20 3727 1051 |
|
Tom Blackwell, Thomas Lodge |
|
|
|
About Mercia Asset Management PLC
Mercia is a private capital asset manager focused on supporting regional SMEs to achieve their growth aspirations. Mercia provides capital across its four asset classes of venture, debt, private equity and proprietary capital: the Group's 'Complete Connected Capital'.
The Group has a strong UK footprint through its 11 regional offices, extensive local adviser and personal networks, and university partnerships, providing it with access to high-quality deal flow.
Mercia Asset Management PLC is quoted on AIM with the EPIC "MERC".
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 4 minutes ago Prudential
- 16 minutes ago Vanquis Banking Group 20
- 2 hours ago Frasers Group
- 2 hours ago Cavendish Financial
- 2 hours ago Diaceutics